



Press Release

FOR IMMEDIATE RELEASE

CRITICAL OUTCOME TECHNOLOGIES INC. APPOINTS NEW MEMBER TO SCIENTIFIC ADVISORY COMMITTEE TO ASSIST WITH PHASE 1B CLINICAL TRIAL

London, Ontario (January 23, 2007): Critical Outcome Technologies Inc. (TSX Venture: COT), announced today that as a result of Company's decision to pursue a Phase 1B Health Canada clinical trial submission with its lead oncology compound COTI-2 it has strengthened its Scientific Advisory Committee with the appointment of Dr. Mark Vincent, a well respected clinical oncologist and clinical trials expert.

"We are delighted with the addition of Dr. Vincent to our Scientific Advisory Committee," said Dr. Wayne Danter, President and CSO of Critical Outcome Technologies Inc. (COTI). "As an internationally respected clinical oncologist and clinical trials expert, Dr. Vincent will be an important contributor to our pursuit of a Phase 1B clinical trial submission with COTI-2. Dr. Vincent has a successful track record in clinical trial design and management with many major Pharmaceutical organizations such as Roche."

Dr. Vincent received his MD from the University of Cape Town in 1976, trained in Oncology at The Royal Marsden Hospital in London, England and came to Canada in 1987. He is a medical oncologist at the London Regional Cancer Program, a part of Cancer Care Ontario, where his activities include the management of lung and gastrointestinal cancer and laboratory research into the reversal of cytotoxic drug resistance by means of gene-directed therapy. His interests include the translation of basic research into the clinic, and the design and conduct of clinical trials in lung and colorectal cancer. Dr. Vincent has extensive experience as a consultant to Canadian and U.S. biotech and pharmaceutical companies. Dr. Vincent is also a member of several other biotechnology scientific advisory boards.

Based on encouraging preclinical results from their lead compound COTI-2, COTI will move immediately to complete the necessary animal pharmacokinetic and toxicity testing required for the submission of an Investigational New Drug (IND) application to Health Canada within the next 12-15 months. Dr. Vincent, an experienced human clinical trials expert will contribute to the design and execution of the Phase 1B clinical trial with COTI-2. The Phase 1B clinical trial will be carried out under the oversight of Health Canada and the Scientific Advisory Committee of COTI.

The current Scientific Advisory Committee now consists of the Chairman, Dr. Wayne Danter, Dr. Jim Koropatnick, Dr. Henrik Hansen, Dr. Brigitte LeBreton and Dr. Mark Vincent.

About Critical Outcome Technologies Inc. (COTI)

COTI is formed around a unique computational platform technology called CHEMSAS[®], which allows for the accelerated identification, profiling and optimization of targeted small molecules potentially effective in the treatment of human diseases for which current therapy is either lacking or ineffective. COTI's business is focused on the discovery and pre-clinical development of libraries of novel, optimized lead molecules for the treatment of specific cancers, HIV and multiple sclerosis. Currently, five targeted libraries of lead compounds



Press Release

(small cell lung cancer, multiple sclerosis, HIV integrase inhibitors, colorectal cancer, and acute myelogenous leukemia in adults) are under active development.

For more information on COTI, please visit www.criticaloutcome.com.

Contact:

Michael Barr, Director of Marketing & Business Development

519-858-5157

mbarr@criticaloutcome.com

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.